Valneva to Present at the Cowen 43rd Annual Healthcare Conference
02 March 2023 - 3:45AM
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
Saint-Herblain
(France), March
1,
2023 – Valneva
SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced that its senior management will present
and participate in 1-on-1 meetings with institutional investors at
the Cowen 43rd Annual Healthcare Conference, to take place
in-person March 6 - 8, 2023 in Boston, Massachusetts.
Key topics to be covered by Chief Executive
Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler
include the Company’s late-stage vaccine candidates targeting
chikungunya (VLA1553) and Lyme disease (VLA15).
The presentation will take place on Tuesday,
March 7, 2022, at 10:30am ET and will be accessible live via the
following link, https://wsw.com/webcast/cowen132/valn/2015538. A
replay of the webcast will be available following the live event in
the “Investors” section of the Valneva website at
www.valneva.com.
To request a meeting at the event, please
contact your representative at Cowen.
About the Cowen Healthcare Conference
Cowen’s 43rd Annual Health Care Conference
will take place March 6 - 8, 2023, at the Boston Marriott
Copley Place in Boston, MA. The conference incorporates
presentations, fireside chats and innovative panel discussions
hosted by members of the Cowen research team that focus on various
aspects of the health care industry.
About Valneva SEValneva is a
specialty vaccine company focused on the development, manufacturing
and commercialization of prophylactic vaccines for infectious
diseases with significant unmet medical need. The Company takes a
highly specialized and targeted approach to vaccine development and
then applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to commercialize
three vaccines and to rapidly advance a broad range of vaccine
candidates into the clinic, including candidates against the
chikungunya virus and Lyme disease.
|
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516
7099laetitia.bachelotfontaine@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor RelationsM +001
917 815 4520joshua.drumm@valneva.com |
|
|
- 2022_03_01_VLA_Cowen_Conference_PR_EN_Final
Valneva (EU:VLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valneva (EU:VLA)
Historical Stock Chart
From Apr 2023 to Apr 2024
